|
Health outcome
|
Main source of variation
|
Population at risk
|
Period of exposure measurement
|
n
|
Fthr
|
Impact
|
CI low (€2006)
|
CI mean (€2006)
|
CI high (€2006)
|
Proportion (mean estimate)
|
|---|
|
Liver cancer
|
Conversion from ingestion dose to blood chlordecone
|
All
|
<2003
|
436 968
|
47 %
|
2.5
|
4 174 000
|
6 213 000
|
12 717 000
|
23 %
|
|
≥2003
|
458 465
|
29 %
|
0.6
|
951 000
|
1 415 000
|
2 896 000
|
11 %
|
|
Annual benefit
| | |
−2.0
|
3 223 000
|
4 798 000
|
9 821 000
|
35 %
|
|
Prostate cancer
|
IC95% of RR
|
Men > 44 years
|
<2003
|
72 566
|
64 %
|
1.8
|
896 000
|
3 286 000
|
6 742 000
|
12 %
|
|
≥2003
|
76 049
|
34 %
|
0.3
|
166 000
|
610 000
|
1 251 000
|
5 %
|
|
Annual benefit
| | |
−1.5
|
730 000
|
2 676 000
|
5 491 000
|
20 %
|
|
Renal dysfunction
|
BMD10-HED
|
Women
|
<2003
|
227 417
|
31 %
|
0.033
|
8 000
|
95 000
|
237 000
|
0.36 %
|
|
≥2003
|
239 470
|
24 %
|
0.011
|
3 000
|
31 000
|
77 000
|
0.24 %
|
|
Annual benefit
| | |
−0.022
|
5 000
|
64 000
|
160 000
|
0.47 %
|
|
Cognitive development
|
Equivalence between QI point and ASQ point
|
Male new born
|
<2003
|
3 747
|
86 %
|
1005.1
|
3 384 000
|
16 922 000
|
33 844 000
|
64 %
|
|
≥2003
|
3 929
|
64 %
|
652.4
|
2 155 000
|
10 779 000
|
21 557 000
|
84 %
|
|
Annual benefit
| | |
−352.7
|
1 229 000
|
6 143 000
|
12 287 000
|
45 %
|
|
Total
| | |
<2003
| | | |
8 462 000
|
26 516 000
|
53 540 000
|
100 %
|
|
≥2003
| | | |
3 275 000
|
12 835 000
|
25 781 000
|
100 %
|
|
Annual benefit
| | | |
5 187 000
|
13 681 000
|
27 759 000
|
100 %
|
-
n = population, 2002 census data for the first period of time and 2006 census data for second period. Fthr = fraction of collective exposure above threshold (for adults threshold = 0.5 μg/kg/d; for pregnant woman and effect on child development (cognitive) = 0.165 μg/kg/d). Impacts are expressed as number of deaths (mean estimate), except for cognitive development where the impacts are expressed in IQ point lost (mean estimate). CI = Cost of Impacts (= DALY * VOLY)
- Impact is the number of cases (Eq. 3), except IQ points for Cognitive development
